Skip to main
PTGX

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics is poised for long-term success due to the positive data coming out of clinical trials and the strong partnerships with companies like Takeda and Johnson & Johnson. Their portfolio of peptide-based therapeutics targeting various diseases shows great potential and their financials are strengthened by recent milestone payments and opt-out fees. The successful launch and continued growth of Icotyde, as well as potential future approvals and partnerships, make Protagonist a strong investment opportunity.

Bears say

Protagonist Therapeutics is a clinical-stage biotechnology company that faces standard risks for this industry, including unexpected outcomes from clinical readouts, regulatory uncertainty, competition risks, commercial risks, manufacturing risks, and financial risks. Furthermore, unexpected safety concerns or unforeseen decisions from strategic partners, as well as increased regulatory, competitive, and pricing risks, could impact the company's rating and price target. Additionally, future cash needs and potential dilution risk are also concerns for this company.

Protagonist Therapeutics (PTGX) has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Strong Buy based on their latest research and market trends.

According to 14 analysts, Protagonist Therapeutics (PTGX) has a Strong Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $144.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $144.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.